$441.37 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter

Equities research analysts predict that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will post $441.37 million in sales for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Jazz Pharmaceuticals’ earnings, with estimates ranging from $428.99 million to $449.74 million. Jazz Pharmaceuticals reported sales of $396.62 million during the same quarter last year, which indicates a positive year-over-year growth rate of 11.3%. The business is scheduled to report its next earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year sales of $441.37 million for the current financial year, with estimates ranging from $1.61 billion to $1.63 billion. For the next fiscal year, analysts anticipate that the company will post sales of $1.85 billion per share, with estimates ranging from $1.79 billion to $1.96 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Jazz Pharmaceuticals.

JAZZ has been the topic of several research analyst reports. Royal Bank of Canada reissued a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, September 15th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 18th. BMO Capital Markets reissued a “buy” rating and issued a $196.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 20th. UBS Group reissued a “buy” rating and issued a $172.00 target price (down from $175.00) on shares of Jazz Pharmaceuticals in a research report on Monday, September 25th. Finally, Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 28th. They issued a “neutral” rating and a $165.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the stock. Jazz Pharmaceuticals has an average rating of “Buy” and an average price target of $181.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded down $1.92 on Friday, hitting $134.65. 317,186 shares of the company traded hands, compared to its average volume of 398,719. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. Jazz Pharmaceuticals has a twelve month low of $106.85 and a twelve month high of $163.75. The firm has a market capitalization of $8,187.44, a PE ratio of 22.18, a PEG ratio of 0.88 and a beta of 0.98.

In related news, Director Patrick G. Enright sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $139.73, for a total value of $1,257,570.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Patrick G. Enright sold 352 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.19, for a total transaction of $46,882.88. Following the completion of the transaction, the director now owns 1,365 shares in the company, valued at approximately $181,804.35. The disclosure for this sale can be found here. Insiders sold 18,552 shares of company stock worth $2,549,643 in the last 90 days. 4.30% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its stake in shares of Jazz Pharmaceuticals by 11,990.7% during the second quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after purchasing an additional 866,691 shares during the period. FMR LLC raised its stake in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after purchasing an additional 849,348 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Jazz Pharmaceuticals by 41.2% during the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after purchasing an additional 410,031 shares during the period. Schroder Investment Management Group purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $52,571,000. Finally, Balyasny Asset Management LLC raised its stake in shares of Jazz Pharmaceuticals by 155.8% during the second quarter. Balyasny Asset Management LLC now owns 270,602 shares of the specialty pharmaceutical company’s stock valued at $42,079,000 after purchasing an additional 164,806 shares during the period. Hedge funds and other institutional investors own 90.73% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “$441.37 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/14/441-37-million-in-sales-expected-for-jazz-pharmaceuticals-plc-jazz-this-quarter.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply